Multiple sclerosis: pathophysiology revisited

Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2.

Author

Per Soelberg Sorensen¹

Affiliation

¹ Copenhagen Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. pss@rh.dk

PMID: 15620850
DOI: 10.1016/S1474-4422(04)00948-2

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
CD4 Antigens / immunology
CD4-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / immunology
Daclizumab
Humans
Immunoglobulin G / therapeutic use
Immunosuppressive Agents / therapeutic use
Multiple Sclerosis / drug therapy
Multiple Sclerosis / immunology
Multiple Sclerosis / physiopathology*
Receptors, Interleukin-2 / immunology
T-Lymphocytes / immunology*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
CD4 Antigens
Immunoglobulin G
Immunosuppressive Agents
Receptors, Interleukin-2
Daclizumab